Edition:
India

aTyr Pharma Inc (LIFE.OQ)

LIFE.OQ on NASDAQ Stock Exchange Capital Market

3.46USD
1:30am IST
Change (% chg)

$0.03 (+0.87%)
Prev Close
$3.43
Open
$3.49
Day's High
$3.49
Day's Low
$3.39
Volume
5,863
Avg. Vol
18,400
52-wk High
$7.62
52-wk Low
$2.15

Latest Key Developments (Source: Significant Developments)

Atyr Pharma Announces $20 Million Common Stock Purchase Agreement With Aspire Capital Fund, Llc
Monday, 14 Sep 2020 

Sept 14 (Reuters) - aTyr Pharma Inc ::ATYR PHARMA ANNOUNCES $20 MILLION COMMON STOCK PURCHASE AGREEMENT WITH ASPIRE CAPITAL FUND, LLC.  Full Article

aTyr Pharma Posts Q2 Loss Per Share Of $0.69
Friday, 14 Aug 2020 

Aug 13 (Reuters) - aTyr Pharma Inc ::ATYR PHARMA ANNOUNCES SECOND QUARTER 2020 RESULTS AND PROVIDES CORPORATE UPDATE ON ATYR1923 CLINICAL TRIAL PROGRAMS.ATYR PHARMA - INITIATED ENROLLMENT OF PHASE 2 RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED STUDY OF ATYR1923 IN COVID-19 PATIENTS.QTRLY LOSS PER SHARE $0.69.Q2 EARNINGS PER SHARE VIEW $-0.73 -- REFINITIV IBES DATA.  Full Article

aTyr Pharma Announces Q1 EPS Of $0.25
Wednesday, 13 May 2020 

May 12 (Reuters) - aTyr Pharma Inc ::ATYR PHARMA ANNOUNCES FIRST QUARTER 2020 RESULTS AND PROVIDES CORPORATE UPDATE ON ATYR1923 CLINICAL TRIALS IN PULMONARY SARCOIDOSIS AND COVID-19.ATYR PHARMA INC - TOTAL REVENUES WERE $8.1 MILLION FOR THREE MONTHS ENDED MARCH 31, 2020, CONSISTING PRIMARILY OF LICENSING REVENUE FROM KYORIN AGREEMENT.ATYR PHARMA INC - QTRLY EARNINGS PER SHARE $0.25.ATYR PHARMA INC - AS OF MARCH 31, 2020, ATYR HAD $49.8 MILLION IN CASH, CASH EQUIVALENTS AND INVESTMENTS.  Full Article

Atyr Announces Phase 2 Study In COVID-19 Patients With Respiratory Complications
Tuesday, 21 Apr 2020 

April 21 (Reuters) - aTyr Pharma Inc ::ATYR PHARMA ANNOUNCES PHASE 2 STUDY OF ATYR1923 IN COVID-19 PATIENTS WITH SEVERE RESPIRATORY COMPLICATIONS FOLLOWING FDA ACCEPTANCE OF IND APPLICATION.ATYR PHARMA INC - ATYR1923 HAS BEEN SHOWN PRE-CLINICALLY TO DOWNREGULATE T-CELL RESPONSES.ATYR PHARMA INC - ATYR1923 HAS ALSO BEEN SHOWN TO IMPROVE LUNG FUNCTION, AS WELL AS TO REDUCE INFLAMMATION AND FIBROSIS.ATYR PHARMA SAYS BELIEVE THERE IS 'STRONG SCIENTIFIC RATIONALE' FOR DEVELOPMENT OF ATYR1923 TO TREAT COVID-19 PATIENTS.  Full Article

Atyr Pharma Expects Delay In Results From Atyr1923 Phase 1b/2a Trial
Friday, 27 Mar 2020 

March 26 (Reuters) - aTyr Pharma Inc ::ATYR PHARMA ANNOUNCES FOURTH QUARTER AND FULL YEAR 2019 RESULTS AND PROVIDES CORPORATE UPDATE.ATYR PHARMA INC - TOTAL REVENUES WERE $0.1 MILLION FOR THREE MONTHS ENDED DEC 31, 2019.ATYR PHARMA INC - AS OF DECEMBER 31, 2019, ATYR HAD $31.1 MILLION IN CASH, CASH EQUIVALENTS AND INVESTMENTS.ATYR PHARMA INC - ANTICIPATES EXITING 2020 WITH OVER $20 MILLION IN CASH, CASH EQUIVALENTS AND INVESTMENTS.ATYR PHARMA - ANTICIPATE THERE WILL BE DELAY IN TOPLINE RESULTS FROM ATYR1923 PHASE 1B/2A CLINICAL TRIAL, WHICH WERE PREVIOUSLY ANTICIPATED IN Q3.  Full Article

Atyr Pharma Files Prospectus For Offering Of Up To $17.25 Mln Shares Of Common Stock
Friday, 17 Jan 2020 

Jan 17 (Reuters) - aTyr Pharma Inc ::ATYR PHARMA INC FILES PROSPECTUS FOR OFFERING OF UP TO $17.25 MILLION SHARES OF COMMON STOCK – SEC FILING.  Full Article

Atyr Posts Qtrly Loss Per Share Of $1.80
Wednesday, 14 Aug 2019 

Aug 14 (Reuters) - aTyr Pharma Inc ::ATYR PHARMA ANNOUNCES SECOND QUARTER 2019 RESULTS AND PROVIDES CORPORATE UPDATE.QTRLY LOSS PER SHARE $1.80.AS OF JUNE 30, 2019, ATYR HAD $42.4 MILLION IN CASH, CASH EQUIVALENTS AND INVESTMENTS.TO REPORT INTERIM SAFETY RESULTS FROM PHASE 1B/2A PROOF-OF-CONCEPT TRIAL OF ATYR1923 IN PULMONARY SARCOIDOSIS PATIENTS IN Q4 2019.  Full Article

Atyr Pharma Announces Reverse Stock Split To Regain Nasdaq Compliance
Saturday, 29 Jun 2019 

June 28 (Reuters) - aTyr Pharma Inc ::ATYR PHARMA ANNOUNCES REVERSE STOCK SPLIT TO REGAIN NASDAQ COMPLIANCE.ANNOUNCES 1 FOR 14 REVERSE STOCK SPLIT.PAR VALUE OF COMPANY'S COMMON STOCK WILL REMAIN UNCHANGED AT $0.001 PER SHARE AFTER REVERSE STOCK SPLIT.ONE-FOR-14 REVERSE STOCK SPLIT IS SCHEDULED TO BECOME EFFECTIVE AFTER TRADING CLOSES ON JUNE 28, 2019.  Full Article

Atyr Pharma Announces Fourth Quarter Results
Tuesday, 26 Mar 2019 

March 25 (Reuters) - aTyr Pharma Inc ::ATYR PHARMA ANNOUNCES FOURTH QUARTER AND FULL YEAR 2018 RESULTS AND PROVIDES CORPORATE UPDATE.ATYR PHARMA INC - AS OF DECEMBER 31, 2018, ATYR HAD $49.5 MILLION IN CASH, CASH EQUIVALENTS AND INVESTMENTS.ATYR PHARMA - AS OF DEC 31, 2018, CO HAD $49.5 MILLION IN CASH, CASH EQUIVALENTS & INVESTMENTS.ATYR PHARMA INC - FOR 2019, CO PROJECTING CASH BURN OF ABOUT $23 MILLION TO $25 MILLION, NET OF DEBT.  Full Article

aTyr Pharma Announces Third Quarter 2018 Operating Results
Wednesday, 14 Nov 2018 

Nov 13 (Reuters) - aTyr Pharma Inc ::ATYR PHARMA ANNOUNCES THIRD QUARTER 2018 OPERATING RESULTS AND PROVIDES CORPORATE UPDATE.ATYR PHARMA INC - INITIATION OF PROOF-OF-CONCEPT STUDY IN PATIENTS WITH PULMONARY SARCOIDOSIS PLANNED FOR Q4 OF 2018.ATYR PHARMA INC - QTRLY LOSS PER SHARE $0.24.  Full Article

BRIEF-Atyr Pharma Highlighted New External Research Demonstrating Involvement Of Neuropilin Biology In Sars-Cov-2 Infection

* ATYR PHARMA INC - HIGHLIGHTED NEW EXTERNAL RESEARCH DEMONSTRATING INVOLVEMENT OF NEUROPILIN BIOLOGY IN SARS-COV-2 INFECTION